COMBINATION CHEMOTHERAPY;
DRUG CONTRAINDICATION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TREATMENT FAILURE;
HUMAN;
JOINT SWELLING;
MONOTHERAPY;
OUTCOME ASSESSMENT;
PRACTICE GUIDELINE;
PRIMARY HEALTH CARE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SHORT SURVEY;
TREATMENT INDICATION;
TREATMENT RESPONSE;
Triple therapy in early active rheumatoid arthritis: A randomized single-blind controlled trial comparing step-up and parallel treatment strategies
Saunders, S. A. et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 58, 1310-1317 (2008).
Evaluation of two strategies initial methotrexate monotherapy vs its combination with adalimumab in management of early active rheumatoid arthritis: Data from the guepard trial
Oxford
Soubrier, M. et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 48, 1429-1434 (2009).
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The image trial
Tak, P. P. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 70, 39-46 (2011).
Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis
Yazici, Y. & Yazici, H. Tumor necrosis factor a inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 449-452 (2008). (Pubitemid 352003214)
Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: A survey of power considerations
DOI 10.1093/rheumatology/ken190
Yazici, Y., Adler, N. M. & Yazici, H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatology (Oxford) 47, 1054-1057 (2008). (Pubitemid 351865932)
(2008)Rheumatology, vol.47, Issue.7, pp. 1054-1057